Correction to: Chromobox Homolog 4 is Correlated with Prognosis and Tumor Cell Growth in Hepatocellular Carcinoma (Annals of Surgical Oncology, (2013), 20, S3, (684-692), 10.1245/s10434-013-3171-7);Chromobox homolog 4 is correlated with prognosis and tumor cell growth in hepatocellular carcinoma

Annals of Surgical Oncology

Volumn 20, Issue 3 SUPPL., 2013, Pages 885-886

  Wang, Boqing ^a,b   Tang, Jianjun ^b   Liao, Dan ^b   Wang, Gang ^b   Zhang, Meifang ^b   Sang, Yi ^b   Cao, Jingying ^b   Wu, Yuanzhong ^b   Zhang, Ruhua ^b   Li, Shengping ^b   Ding, Wei ^a   Zhang, Guoqing ^a   Kang, Tiebang ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CBX4 PROTEIN, HUMAN; MESSENGER RNA; POLYCOMB GROUP PROTEIN; SMALL INTERFERING RNA; TUMOR MARKER; UBIQUITIN PROTEIN LIGASE;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; CANCER STAGING; CELL PROLIFERATION; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYCOMB-GROUP PROTEINS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN-PROTEIN LIGASES;

EID: 84892795727     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-021-10400-8     Document Type: Erratum

References (34)

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264-73.e1.
2. Chen D, Xing W, Hong J, et al. The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection. Ann Surg Oncol. 2012;19:3556-65.
3. Li JJ, Pan K, Gu MF, et al. Prognostic value of soluble MICA levels in the serum of patients with advanced hepatocellular carcinoma. Chin J Cancer. 2013;32:141-8.
4. Yi Y, Wu H, Gao Q, et al. Interferon regulatory factor (IRF)-1 and IRF-2 are associated with prognosis and tumor invasion in HCC. Ann Surg Oncol. 2013;20:267-76.
5. Song TJ, Fong Y, Cho SJ, et al. Comparison of hepatocellular carcinoma in American and Asian patients by tissue array analysis. J Surg Oncol. 2012;106:84-8.
6. Richly H, Aloia L, Di Croce L. Roles of the Polycomb group proteins in stem cells and cancer. Cell Death Dis. 2011;2:e204.
7. Vandamme J, Volkel P, Rosnoblet C, Le Faou P, Angrand PO. Interaction proteomics analysis of polycomb proteins defines distinct PRC1 complexes in mammalian cells. Mol Cell Proteomics. 2011;10:M110 002642.
8. Gao Z, Zhang J, Bonasio R, et al. PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes. Mol Cell. 2012;45:344-56.
9. Bracken AP, Helin K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer. 2009; 9:773-84.
10. Forzati F, Federico A, Pallante P, et al. CBX7 is a tumor suppressor in mice and humans. J Clin Invest. 2012;122:612-23.
11. Tan J, Jones M, Koseki H, et al. CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell. 2011;20:563-75.
12. Yang L, Lin C, Liu W, et al. ncRNA- and Pc2 methylationdependent gene relocation between nuclear structures mediates gene activation programs. Cell. 2011;147:773-88.
13. Xu S, Feng Z, Zhang M, et al. hSSB1 binds and protects p21 from ubiquitin-mediated degradation and positively correlates with p21 in human hepatocellular carcinomas. Oncogene. 2011;30:2219-29.
14. Hong J, Hu K, Yuan Y, et al. CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma. J Clin Invest. 2012;122:2165-75.
15. Tang QL, Xie XB, Wang J, et al. Glycogen synthase kinase- 3beta, NF-kappaB signaling, and tumorigenesis of human osteosarcoma. J Natl Cancer Inst. 2012;104:749-63.
16. Remmele W, Schicketanz KH. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract. 1993;189:862-6.
17. Xu S, Wu Y, Chen Q, et al. hSSB1 regulates both the stability and the transcriptional activity of p53. Cell Res. 2013;23:423-35.
18. Kang T, Wei Y, Honaker Y, et al. GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell. 2008;13:36-47.
19. Chen R, Zhu D, Ye X, Shen D, Lu R. Establishment of three human liver carcinoma cell lines and some of their biological characteristics in vitro. Sci Sin. 1980;23:236-47.
20. Wang JB. Establishment and some characteristics of a hepatoma cell line (QGY-7703). Zhonghua Zhong Liu Za Zhi. 1981;3:241-4.
21. Kagey MH, Melhuish TA, Wotton D. The polycomb protein Pc2 is a SUMO E3. Cell. 2003;113:127-37.
22. Ismail IH, Gagne JP, Caron MC, et al. CBX4-mediated SUMO modification regulates BMI1 recruitment at sites of DNA damage. Nucleic Acids Res. 2012;40:5497-510.
23. O'Loghlen A, Munoz-Cabello AM, Gaspar-Maia A, et al. MicroRNAregulation of Cbx7 mediates a switch of Polycomb orthologs during ESC differentiation. Cell Stem Cell. 2012;10:33-46.
24. Pallante P, Federico A, Berlingieri MT, et al. Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Res. 2008;68:6770-8.
25. McGivern DR, Lemon SM. Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. Annu Rev Pathol. 2009;4:399-415.
26. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153-66.
27. Wang X, Meng X, Sun X, et al. Wnt/beta-catenin signaling pathway may regulate cell cycle and expression of cyclin A and cyclin E protein in hepatocellular carcinoma cells. Cell Cycle. 2009;8:1567-70.
28. Stroescu C, Dragnea A, Ivanov B, et al. Expression of p53, Bcl-2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma. J Gastrointestin Liver Dis. 2008;17:411-7.
29. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006;6:846-56.
30. Ruddock-D'Cruz NT, Prashadkumar S, Wilson KJ, et al. Dynamic changes in localization of Chromobox (Cbx) family members during the maternal to embryonic transition. Mol Reprod Dev. 2008;75:477-88.
31. Huynh H. Overexpression of tumour suppressor retinoblastoma 2 protein (pRb2/p130) in hepatocellular carcinoma. Carcinogenesis. 2004;25:1485-94.
32. Reno EM, Haughian JM, Dimitrova IK, Jackson TA, Shroyer KR, Bradford AP. Analysis of protein kinase C delta (PKC delta) expression in endometrial tumors. Hum Pathol. 2008; 39:21-9.
33. Roscic A, Moller A, Calzado MA, et al. Phosphorylationdependent control of Pc2 SUMO E3 ligase activity by its substrate protein HIPK2. Mol Cell. 2006;24:77-89.
34. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136:629-41.